KINDAL BURLESON: Open Payments
NPI 1740736008 · SPARTANBURG, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$892 in 50 payments from 20 companies in 2025. Trend: 2023 $2,970 · 2024 $1,650 · 2025 $892
Food & beverage: $892
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $150 |
| ABBVIE INC. | 11 | $149 |
| Novartis Pharmaceuticals Corporation | 5 | $94 |
| Corcept Therapeutics | 4 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| Esperion Therapeutics, Inc. | 2 | $48 |
| PFIZER INC. | 3 | $47 |
| Dexcom, Inc. | 2 | $41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| Amgen Inc. | 2 | $33 |
Products named: BREZTRI, LEQVIO, Korlym, VOQUEZNA, NEXLETOL, VRAYLAR, LINZESS, JARDIANCE.
Industry payments across SC — which companies pay providers there.
